
Invega Sustenna Coupons & Savings Card – Discount Prices from $2291.82
My prescription
Edit
1ML of 156MG/ML, Invega Sustenna (1 Syringe)
Select pharmacy

CVS
$2422.41
COUPON PRICE
Albertsons
$2291.82
COUPON PRICE
Walgreens
$2503.60
COUPON PRICE
Walmart
$2510.20
COUPON PRICEInvega Sustenna savings card
Show this card to your pharmacist
Albertsons
$2291.82
BIN
ID
PCN
GRP
015995
LHKPW636250
GDC
DR33
Powered by
More prescriptions for schizophrenia
More prescriptions for schizophrenia
Price history for Invega Sustenna
1 Syringe, 1ML of 156MG/ML
Average retail price for Invega Sustenna
Average SaveHealth price for Invega Sustenna
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Invega Sustenna dosage forms
Dosage Quantity Price from Per unit 0.25ML of 39MG/0.25ML 1 Syringe $599.77 $599.77 0.25ML of 39MG/0.25ML 2 Syringes $1184.53 $592.26 0.25ML of 39MG/0.25ML 3 Syringes $1769.30 $589.77 0.5ML of 78MG/0.5ML 1 Syringe $1183.85 $1183.85 0.5ML of 78MG/0.5ML 2 Syringes $2352.71 $1176.36 0.5ML of 78MG/0.5ML 3 Syringes $3521.56 $1173.85 0.75ML of 117MG/0.75ML 1 Syringe $1770.06 $1770.06 0.75ML of 117MG/0.75ML 2 Syringes $3525.12 $1762.56 0.75ML of 117MG/0.75ML 3 Syringes $5280.18 $1760.06 1ML of 156MG/ML 1 Syringe $2354.65 $2354.65
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.25ML of 39MG/0.25ML | 1 Syringe | $599.77 | $599.77 |
| 0.25ML of 39MG/0.25ML | 2 Syringes | $1184.53 | $592.26 |
| 0.25ML of 39MG/0.25ML | 3 Syringes | $1769.30 | $589.77 |
| 0.5ML of 78MG/0.5ML | 1 Syringe | $1183.85 | $1183.85 |
| 0.5ML of 78MG/0.5ML | 2 Syringes | $2352.71 | $1176.36 |
| 0.5ML of 78MG/0.5ML | 3 Syringes | $3521.56 | $1173.85 |
| 0.75ML of 117MG/0.75ML | 1 Syringe | $1770.06 | $1770.06 |
| 0.75ML of 117MG/0.75ML | 2 Syringes | $3525.12 | $1762.56 |
| 0.75ML of 117MG/0.75ML | 3 Syringes | $5280.18 | $1760.06 |
| 1ML of 156MG/ML | 1 Syringe | $2354.65 | $2354.65 |
| 1ML of 156MG/ML | 2 Syringes | $4694.29 | $2347.14 |
| 1ML of 156MG/ML | 3 Syringes | $7033.94 | $2344.65 |
| 1.5ML of 234MG/1.5ML | 1 Syringe | $3525.62 | $3525.62 |
| 1.5ML of 234MG/1.5ML | 2 Syringes | $7036.25 | $3518.13 |
| 1.5ML of 234MG/1.5ML | 3 Syringes | $10546.87 | $3515.62 |
What is INVEGA SUSTENNA injection used for?
INVEGA SUSTENNA is an antipsychotic medication used for the treatment of schizophrenia and schizoaffective disorder in adults. It helps manage symptoms such as hallucinations, delusions, and mood disturbances.
Is Invega the same as Abilify?
Invega and Abilify are not the same. They are both antipsychotic medications but have different active ingredients and may be used to treat different conditions. Invega contains paliperidone, while Abilify contains aripiprazole. Their mechanisms of action and side effect profiles also differ. It is important for patients to follow their healthcare provider's guidance when using these medications.
What are the most common side effects of INVEGA SUSTENNA?
The most common side effects of INVEGA SUSTENNA include injection site reactions, drowsiness, dizziness, headache, and weight gain. Other frequently reported side effects are increased heart rate, restlessness, and gastrointestinal issues such as nausea and constipation. It's important for patients to discuss any side effects with their healthcare provider.
What does the Invega shot help with?
The Invega shot, also known as paliperidone palmitate, is used to help manage symptoms of schizophrenia and schizoaffective disorder. It works by helping to restore the balance of certain neurotransmitters in the brain, which can reduce symptoms such as hallucinations, delusions, and mood disturbances.
What is the warning on INVEGA SUSTENNA?
INVEGA SUSTENNA carries a warning for an increased risk of mortality in elderly patients with dementia-related psychosis. It is not approved for the treatment of patients with dementia-related psychosis. Additionally, there is a risk of cerebrovascular adverse events, including stroke, in this population. It is important for healthcare providers to consider these risks when prescribing this medication.
